Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. - Wikidata - awgldk - TriplyDB

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q35115629

about

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer Development of Companion Diagnostics Advances in molecular imaging for breast cancer detection and characterization Role of positron emission tomography for the monitoring of response to therapy in breast cancer Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response.IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.Meeting the challenges of PET-based molecular imaging in cancer.18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel Fulvestrant and male breast cancer: a pooled analysis.18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.Effect of anti-PMSG on distribution of estrogen receptor alpha and progesterone receptor in mouse ovary, oviduct and uterus.Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.

P2860

Q26740567-CE3D6A5B-1FCF-4AF7-9B20-FF5DDE774951 Q26772868-6085C7CB-5FCE-41E3-8999-A71E7ACFD955 Q26774670-20BF597E-1F21-4C49-A53C-09DD2ADAC76B Q27000462-C90BDC8C-4DCC-4CC4-9407-8013CD1D3D39 Q28080621-74A6EDDA-D065-4EE4-BF08-84B3486C6FA4 Q34068083-26208CA8-78A5-40A4-A580-482C5839B856 Q34518285-A29792E8-CDD7-4410-A9E1-89E6A6531E35 Q34534031-4357D9DE-B2A6-4B7B-A26F-BF6F2D42C4EA Q35143049-B9CB2C3A-CB1F-4404-A164-6DE21312411F Q35178385-0CFEB99D-148A-4355-AA1A-3278FA2E6B0B Q35502637-4BF715D3-E9C4-4126-8FD5-AB712CB2676F Q36301166-F5689C80-4323-410F-87F7-A0B52671A9DD Q36344573-B372FC13-6216-4831-8D44-9396B7CE2B4D Q36429530-63A6A2BA-0495-4C43-B4FB-E557C0699D68 Q37641611-D90A4CBA-0165-49AC-9DA1-D32268E9A513 Q38090509-024DCC02-5DC9-4F42-8F3A-D27D0D74C6B4 Q38631164-94A63D14-B2AC-4935-8B2B-6B0C2D02FCAE Q38800009-57100B5A-02A3-497B-AC62-9F13955F18E1 Q38836364-BDD45590-0380-4D9C-9B0E-5EDD0EC05DFC Q39160175-AE3DD569-D43D-4483-A49D-637D8DB175BB Q39345390-4AC3E401-E7D6-419D-89FA-CB6C824CA2D6 Q40409656-3DF3A99E-0650-4BCD-91D8-EF47E63AD3A8 Q41140406-73CAD953-531D-436F-A0BB-ADBA42EB5D9E Q41677482-E4E1D555-DB28-45D2-B340-50F34B55811B Q47732227-B9EADECA-44A2-41F9-AA4D-695B8BACD301 Q51114179-F16DA57B-BD28-4534-A0DA-CC1927485A76 Q51116267-8BBF0F36-A04A-4C9B-AF86-7562C2690E2F Q51311647-0ADAA92C-AEC6-4BEC-8CBE-02369E393051

P2860

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q35115629

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@ast

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@en

type

label

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@ast

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@en

prefLabel

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@ast

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@en

P1433

Q35115629-0FF62996-9E57-407A-BFCF-8E72D90BCFE0

P1476

Q35115629-D9DBA2C6-CD1F-4FEE-A9E4-1011495DD2CD

P2093

Q35115629-081424F4-D156-471F-B00B-CB9FD67EF53F

Q35115629-23D2411D-616D-498E-9986-DCBBD6C198C0

Q35115629-2BE2E078-61FC-42AE-9482-AA5C6B60E095

Q35115629-31DBC839-5F64-471E-A68F-B52CA172B1D1

Q35115629-437FBA45-81A2-4A48-BE30-CE2AB895E768

Q35115629-67D44AA2-4DA3-4E08-A2F5-4E2481346717

Q35115629-78DE2BAA-4694-4856-8ACA-D1A9B8959F56

Q35115629-7F5A0D38-8C43-4AF5-AD41-38C83431E760

Q35115629-819E9480-B0F7-44BE-9122-1FD43340CC4A

Q35115629-8A5B4980-5500-41E0-8D63-59E09E1206C7

P2860

Q35115629-0E2F3E48-F70B-46D4-A4FC-09C0338674CE

Q35115629-2699E4FC-A846-4B76-890B-3189ABB337D2

Q35115629-2E0BB598-24B4-4342-99A3-5CAD52C9D369

Q35115629-39FDE664-BE41-4AB9-B229-6710BD8B8145

Q35115629-3A7F9CDB-C31C-4E04-AC11-B1A28BF609AB

Q35115629-3B81D675-38CC-48E2-8537-FF2CEE757727

Q35115629-3BBBB86D-DCCD-4E11-80FC-9845062D2ED5

Q35115629-48781F41-1DB6-43DF-998C-E13F20EBB6F7

Q35115629-57C80C73-9519-4C3A-9EF4-82AD18C9BA70

Q35115629-63A08146-C93B-40EF-BC2E-9C250C4F5B20

P304

Q35115629-00252BBC-F21E-41B6-99A5-10801AA57827

P31

Q35115629-0A592A0F-A6ED-4A2F-8625-74DE0B38A76A

P356

Q35115629-6C5FB021-E1F2-479D-806D-0E6E092DFA41

P407

Q35115629-C559D95F-07DA-4784-B166-4E75A645457D

P433

Q35115629-F111A14E-45D8-449E-A6C7-A48A73D61E1B

P478

Q35115629-0188F611-F72C-4B49-9050-6BE432E4CB43

P577

Q35115629-215DD59F-2265-4AB1-AE94-E5453894AB03

P698

Q35115629-EF051E0B-4AA9-437B-82A1-AF49E39B2174

P932

Q35115629-87A96D64-AE36-483D-A081-21EA3B32DCF2

P356

1078-0432.CCR-10-3321

P1433

Clinical Cancer Research

P1476

Fluoroestradiol positron emiss ...... with metastatic breast cancer.

@en

P2093

Brenda F Kurland

http://www.w3.org/2001/XMLSchema#string

David A Mankoff

http://www.w3.org/2001/XMLSchema#string

Erin K Schubert

http://www.w3.org/2001/XMLSchema#string

Georgiana K Ellis

http://www.w3.org/2001/XMLSchema#string

Hannah M Linden

http://www.w3.org/2001/XMLSchema#string

Jeanne M Link

http://www.w3.org/2001/XMLSchema#string

Jennifer M Specht

http://www.w3.org/2001/XMLSchema#string

Julie R Gralow

http://www.w3.org/2001/XMLSchema#string

Kenneth A Krohn

http://www.w3.org/2001/XMLSchema#string

Lanell M Peterson

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.

Exact inference for categorical data: recent advances and continuing controversies.

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

The role of aromatase inhibitors in early breast cancer.

The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.

Estrogen-receptor biology: continuing progress and therapeutic implications.

Clinical development of fulvestrant ("Faslodex").

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.

P304

4799-4805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-3321

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21750198

http://www.w3.org/2001/XMLSchema#string

P932

3139698

http://www.w3.org/2001/XMLSchema#string